Specificity, Phenotype and Function of Pancreatic CD8 T Cells in Human Type 1 Diabetes

人类 1 型糖尿病中胰腺 CD8 T 细胞的特异性、表型和功能

基本信息

项目摘要

PROJECT SUMMARY Human type 1 diabetes (T1D) is characterized by the immune-mediated destruction of insulin-producing pancreatic beta cells. CD8 T cells are the most common [immune] cell found in insulitic lesions and are the principal T cell type implicated in beta cell destruction. Studies performed within this project have already revealed significant [and novel] findings including: 1) the first identification of auto-reactive CD8 T cells in the islets of patients with T1D using a specially [designed method of] tetramer staining and 2) [the first description of high] numbers of CD8 T cells infiltrating the exocrine pancreas in T1D patients compared with non-diabetic individuals. Based on these findings, we anticipate that only a proportion of the cells that infiltrate the pancreas are indeed auto-reactive. Thus, the pool of `bystander' CD8 T cells that recognize other, for example viral, antigens might significantly contribute to the inflammatory environment of the organ. At present, the overall specificities and frequencies of CD8 T cells in the pancreas and the cause for their entry and activation are not fully understood. Possible targets are known autoantigens derived from beta cells such as insulin, IGRP, IA-2 and GAD (see Table 2 for abbreviations) and cellular matrix proteins, which could become presented [and modified] when beta cells are destroyed, but viral proteins, for example enteroviral determinants are also possible candidates. The overall objective of this renewal application is therefore to compare the specificity, phenotype and function of CD8 T lymphocytes from human islets with those found in exocrine tissue, and to assess whether their presence correlates with islet-specific pathology (e.g. viral infections and their detectable footprints). We will study patients with recent-onset and longstanding T1D in order to build a road map of specificities and to further understand how the relationship between the CD8 T cell infiltrate and the disease course might evolve [both quantitatively and qualitatively over time. A unique strength is not only the access to very unique organ repositories but also the newly established collaboration with Dr. Alessandro Sette and Dr. Bjoern Peters' laboratories, which maintain the Immune Epitope Database (IEDB) at La Jolla institute and are part of an epitope discovery initiative led by Novo Nordisk. Using the information contained in the IEDB and in vitro assays, neo-epitopes to modified autoantigens and new viral CD8 T cell epitopes restricted to HLA-A2 will be mapped and the information shared with our laboratory. Overall, our findings should give us a better understanding of how and why T1D develops and thus help ultimately with the development of new therapeutic options.] Our first goal is to systematically and quantitatively detect autoreactive CD8 T cells within human islets and exocrine pancreas and to correlate the number and activation status of these cells with the local histopathology of the organ. In situ tetramer staining of freshly frozen human pancreata available from the Network for Pancreatic Organ Donors with Diabetes (nPOD), the Diabetes Biobank Brussels (DBB) and the Biobank at Oslo University Hospital will be performed. [The discovery of new post-translationally-modified epitopes using the information contained in the IEDB and the expertise at La Jolla Institute in conjunction with our experiments in situ will provide, for the first time,] information on the precise tissue distribution of antigen- specific CD8 T cells in the pancreas. In addition, we will further characterize their phenotype and function. This will allow for the identification of key antigens with significant polarization towards the islets, which are more likely to be involved in the pathogenesis of disease. It will also help us to understand why exocrine pancreas inflammation is often present in T1D. Our second goal is to search for virus-specific T cells within islets and exocrine tissue. [This will help to ascertain whether one virus might trigger the disease (hit-and-run event) or whether numerous viral attacks are required (multiple hits) or several viral strains of the same genus or even different viruses that trigger common pathways might play a role in the pathogenesis of the disease (multiple viruses)]. Pancreas tissue sections from donors with recent-onset and long duration of T1D will therefore be probed with virus-specific tetramers, and we will detect any viral proteins and nucleic acids in these samples in collaboration with the nPOD-Virology group in order to investigate the manner of viral infection (hit-and-run; multiple hits or multiple viruses). We will initially focus our attention on enteroviruses (EV), as only the association with group B coxsackieviruses has thus far been sufficiently documented. [For this purpose, we will aim to identify new EV epitopes through our collaboration with Dr. Sette and Dr. Peters' laboratories and the use of the IEDB as well as their expertise on the discovery and validation of cytotoxic and T cell epitopes presented by HLA Class I molecules]. The frequency of EV-specific cells will be compared to that of other common viruses such as cytomegalovirus (CMV) and Epstein-Barr virus (EBV). We will also investigate the possible presence of herpesvirus-6 (HHV6) and HHV6-specific CD8 T cells, because recent evidence suggests that this virus might be present in the pancreas of T1D donors. In addition, we will correlate our findings with the local histopathology of the organ (MHC-I expression, interferon signature, CD8 T cell phenotype, cytokine production and presence/absence of viral protein or genome).
项目摘要 人1型糖尿病(T1 D)的特征在于免疫介导的对胰岛素产生细胞的破坏。 胰腺β细胞CD 8 T细胞是胰岛炎病变中最常见的[免疫]细胞, 参与β细胞破坏的主要T细胞类型。在该项目中进行的研究已经 揭示了重要的[和新的]发现,包括:1)首次鉴定出自体反应性CD 8 T细胞在 使用特别[设计的]四聚体染色的T1 D患者的胰岛和2)[第一描述 与非糖尿病患者相比,T1 D患者中浸润胰腺外分泌的CD 8 T细胞数量较高 个体基于这些发现,我们预计只有一部分浸润胰腺的细胞 是自动反应的因此,识别其他,例如病毒, 抗原可能对器官的炎症环境有显著贡献。目前整体 胰腺中CD 8 T细胞的特异性和频率以及它们进入和激活的原因并不清楚。 完全理解可能的靶点是已知的来源于β细胞的自身抗原,如胰岛素、HRP、IA-2 和GAD(缩写见表2)和细胞基质蛋白,这些蛋白可以被呈递[和 当β细胞被破坏时,病毒蛋白,例如肠道病毒决定簇也被破坏。 可能的候选人。因此,本次更新申请的总体目标是比较 人胰岛CD 8 T淋巴细胞的特异性、表型和功能与 外分泌组织,并评估它们的存在是否与胰岛特异性病理学相关(例如, 病毒感染及其可检测的足迹)。我们将研究近期发作和长期 T1 D,以建立具体性路线图,并进一步了解 CD 8 T细胞浸润和疾病过程可能随着时间的推移而演变[定量和定性。一 独特的优势不仅在于能够获得非常独特的器官储存库,而且还在于新建立的 与Alessandro Sette博士和Bjoern Peters博士的实验室合作, 表位数据库(IEDB)在拉霍亚研究所,是一个表位发现计划的一部分,由诺 诺德。使用IEDB和体外测定中包含的信息,修饰的新表位可以在体外测定。 自身抗原和新的病毒CD 8 T细胞表位限制到HLA-A2将被映射和信息 与我们的实验室分享。总的来说,我们的研究结果应该让我们更好地了解T1 D如何以及为什么 发展,从而最终有助于新的治疗选择的发展。 我们的第一个目标是系统地和定量地检测人类胰岛内的自身反应性CD 8 T细胞, 外分泌胰腺,并将这些细胞的数量和激活状态与局部 器官的组织病理学。新鲜冷冻人胰腺的原位四聚体染色,可从 糖尿病胰腺器官捐献者网络(nPOD)、布鲁塞尔糖尿病生物库(DBB)和 将在奥斯陆大学医院进行生物样本库检查。[The发现新的后修饰的 表位使用IEDB中包含的信息和拉霍亚研究所的专业知识, 我们的原位实验将首次提供关于抗原的精确组织分布的信息- 胰腺中的特异性CD 8 T细胞。此外,我们将进一步表征其表型和功能。这 将允许鉴定对胰岛具有显著极化的关键抗原, 可能参与疾病的发病机制。这也将帮助我们理解为什么胰腺外分泌 炎症通常存在于T1 D中。 我们的第二个目标是在胰岛和外分泌组织中寻找病毒特异性T细胞。[This将有助于 确定是否一种病毒可能引发疾病(肇事逃逸事件)或是否多次病毒攻击 需要(多次命中)或相同属的几种病毒株或甚至不同的病毒, 共同途径可能在疾病的发病机制中起作用(多种病毒)]。胰腺组织 因此,将用病毒特异性探针探测来自最近发作且持续时间较长的T1 D供体的切片。 四聚体,我们将检测这些样品中的任何病毒蛋白质和核酸, nPOD-病毒学小组,以研究病毒感染的方式(打了就跑;多次击中或多次击中) 病毒)。我们首先将注意力集中在肠道病毒(EV)上,因为只有与B组的关联 柯萨奇病毒迄今已有充分的文献记载。[For为此,我们将致力于确定新的EV 表位通过我们的合作与博士塞特和博士彼得斯的实验室和使用IEDB以及 由于他们在发现和验证HLA I类呈递的细胞毒性和T细胞表位方面的专业知识, 分子]。EV特异性细胞的频率将与其他常见病毒的频率进行比较, 巨细胞病毒(CMV)和EB病毒(EBV)。我们还将调查可能存在的 疱疹病毒-6(HHV 6)和HHV 6特异性CD 8 T细胞,因为最近的证据表明,这种病毒可能 存在于T1 D捐赠者的胰腺中。此外,我们将把我们的发现与当地的 器官的组织病理学(MHC-I表达、干扰素特征、CD 8 T细胞表型、细胞因子 病毒蛋白或基因组的产生和存在/不存在)。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Matthias G. Von Herrath其他文献

Matthias G. Von Herrath的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Matthias G. Von Herrath', 18)}}的其他基金

Treg stability in viral infection and autoimmunity
病毒感染和自身免疫中 Treg 的稳定性
  • 批准号:
    8495227
  • 财政年份:
    2013
  • 资助金额:
    $ 45万
  • 项目类别:
Treg stability in viral infection and autoimmunity
病毒感染和自身免疫中 Treg 的稳定性
  • 批准号:
    8377922
  • 财政年份:
    2012
  • 资助金额:
    $ 45万
  • 项目类别:
Specificity of CD8 cells in islets from type 1 diabetes patients
1 型糖尿病患者胰岛中 CD8 细胞的特异性
  • 批准号:
    8655830
  • 财政年份:
    2011
  • 资助金额:
    $ 45万
  • 项目类别:
Specificity of CD8 cells in islets from type 1 diabetes patients
1 型糖尿病患者胰岛中 CD8 细胞的特异性
  • 批准号:
    8261913
  • 财政年份:
    2011
  • 资助金额:
    $ 45万
  • 项目类别:
Specificity of CD8 cells in islets from type 1 diabetes patients
1 型糖尿病患者胰岛中 CD8 细胞的特异性
  • 批准号:
    8195256
  • 财政年份:
    2011
  • 资助金额:
    $ 45万
  • 项目类别:
Specificity of CD8 cells in islets from type 1 diabetes patients
1 型糖尿病患者胰岛中 CD8 细胞的特异性
  • 批准号:
    8451478
  • 财政年份:
    2011
  • 资助金额:
    $ 45万
  • 项目类别:
Specificity of CD8 cells in islets from type 1 diabetes patients
1 型糖尿病患者胰岛中 CD8 细胞的特异性
  • 批准号:
    8828063
  • 财政年份:
    2011
  • 资助金额:
    $ 45万
  • 项目类别:
Specificity, Phenotype and Function of Pancreatic CD8 T Cells in Human Type 1 Diabetes
人类 1 型糖尿病中胰腺 CD8 T 细胞的特异性、表型和功能
  • 批准号:
    10061526
  • 财政年份:
    2011
  • 资助金额:
    $ 45万
  • 项目类别:
Treg stability in viral infection and autoimmunity
病毒感染和自身免疫中 Treg 的稳定性
  • 批准号:
    8006796
  • 财政年份:
    2010
  • 资助金额:
    $ 45万
  • 项目类别:
How IL-10R blockade can resolve persistent viral infections
IL-10R 阻断如何解决持续性病毒感染
  • 批准号:
    7919813
  • 财政年份:
    2009
  • 资助金额:
    $ 45万
  • 项目类别:

相似国自然基金

Neo-antigens暴露对肾移植术后体液性排斥反应的影响及其机制研究
  • 批准号:
    2022J011295
  • 批准年份:
    2022
  • 资助金额:
    10.0 万元
  • 项目类别:
    省市级项目
结核分枝杆菌持续感染期抗原(latency antigens)的重组BCG疫苗研究
  • 批准号:
    30801055
  • 批准年份:
    2008
  • 资助金额:
    19.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

Bovine herpesvirus 4 as a vaccine platform for African swine fever virus antigens in pigs
牛疱疹病毒 4 作为猪非洲猪瘟病毒抗原的疫苗平台
  • 批准号:
    BB/Y006224/1
  • 财政年份:
    2024
  • 资助金额:
    $ 45万
  • 项目类别:
    Research Grant
A novel vaccine approach combining mosquito salivary antigens and viral antigens to protect against Zika, chikungunya and other arboviral infections.
一种结合蚊子唾液抗原和病毒抗原的新型疫苗方法,可预防寨卡病毒、基孔肯雅热和其他虫媒病毒感染。
  • 批准号:
    10083718
  • 财政年份:
    2023
  • 资助金额:
    $ 45万
  • 项目类别:
    Small Business Research Initiative
Uncovering tumor specific antigens and vulnerabilities in ETP-acute lymphoblastic leukemia
揭示 ETP-急性淋巴细胞白血病的肿瘤特异性抗原和脆弱性
  • 批准号:
    480030
  • 财政年份:
    2023
  • 资助金额:
    $ 45万
  • 项目类别:
    Operating Grants
Regulation of B cell responses to vaccines by long-term retention of antigens in germinal centres
通过在生发中心长期保留抗原来调节 B 细胞对疫苗的反应
  • 批准号:
    MR/X009254/1
  • 财政年份:
    2023
  • 资助金额:
    $ 45万
  • 项目类别:
    Research Grant
Adaptive Discrimination of Risk of Antigens in Immune Memory Dynamics
免疫记忆动态中抗原风险的适应性辨别
  • 批准号:
    22KJ1758
  • 财政年份:
    2023
  • 资助金额:
    $ 45万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
22-ICRAD Call 2 - Improving the diagnosis of tuberculosis in domestic ruminants through the use of new antigens and test platforms
22-ICRAD 呼吁 2 - 通过使用新抗原和测试平台改善家养反刍动物结核病的诊断
  • 批准号:
    BB/Y000927/1
  • 财政年份:
    2023
  • 资助金额:
    $ 45万
  • 项目类别:
    Research Grant
Protective immunity elicited by distinct polysaccharide antigens of classical and hypervirulent Klebsiella
经典和高毒力克雷伯氏菌的不同多糖抗原引发的保护性免疫
  • 批准号:
    10795212
  • 财政年份:
    2023
  • 资助金额:
    $ 45万
  • 项目类别:
Integrative proteome analysis to harness humoral immune response against tumor antigens
综合蛋白质组分析利用针对肿瘤抗原的体液免疫反应
  • 批准号:
    23K18249
  • 财政年份:
    2023
  • 资助金额:
    $ 45万
  • 项目类别:
    Grant-in-Aid for Challenging Research (Exploratory)
Targeting T3SA proteins as protective antigens against Yersinia
将 T3SA 蛋白作为针对耶尔森氏菌的保护性抗原
  • 批准号:
    10645989
  • 财政年份:
    2023
  • 资助金额:
    $ 45万
  • 项目类别:
Functionally distinct human CD4 T cell responses to novel evolutionarily selected M. tuberculosis antigens
功能独特的人类 CD4 T 细胞对新型进化选择的结核分枝杆菌抗原的反应
  • 批准号:
    10735075
  • 财政年份:
    2023
  • 资助金额:
    $ 45万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了